Peptide Receptor Radionuclide Therapy for Belfast comes from Novartis
- Belfast Health and Social Care Trust
- Northern Ireland
- Direct
- 24 November 2025 to 31 December 2026
Belfast Health and Social Care Trust is buying peptide receptor radionuclide therapy (PRRT) from Novartis Pharmaceuticals UK Limited. The radiopharmaceutical treatment is for patients in the trust's hospital care.
Novartis supplies the treatment for clinical use. The trust awarded Novartis the 13-month, £1.82m contract directly in November 2025, and the contract runs to December 2026.
Contract ends December 2026
- What
- Radiopharmaceuticals and contrast media
- Value
- £1.82m
- How it was bought
- Direct
- Dates and next
- Nov 2025 to Dec 2026